Handbook of targeted cancer therapy and immunotherapy /:
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Philadelphia :
Wolters Kluwer,
[2023]
|
| Ausgabe: | Third edition. |
| Schlagworte: | |
| Online-Zugang: | DE-862 DE-863 |
| Beschreibung: | Includes index. |
| Beschreibung: | 1 online resource. |
| ISBN: | 9781975179267 1975179269 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1434576124 | ||
| 003 | OCoLC | ||
| 005 | 20250103110447.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 240521s2023 pau of 000 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d OCLCO |d QGK | ||
| 020 | |a 9781975179267 |q (electronic bk.) | ||
| 020 | |a 1975179269 |q (electronic bk.) | ||
| 020 | |z 9781975179243 | ||
| 035 | |a (OCoLC)1434576124 | ||
| 050 | 4 | |a RC271.C5 |b H36 2023 | |
| 082 | 7 | |a 616.994061 |2 23/eng/20240523 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Handbook of targeted cancer therapy and immunotherapy / |c editers, Daniel D. Karp, Gerald S. Falchook, JoAnn D. Lim. |
| 250 | |a Third edition. | ||
| 264 | 1 | |a Philadelphia : |b Wolters Kluwer, |c [2023] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | |a Online resource; title from PDF title page (EBSCO, viewed May 23, 2024). | ||
| 500 | |a Includes index. | ||
| 505 | 0 | |a Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgments -- Contents -- SECTION 1 Targets by Organ Site -- Color Key -- Abbreviations -- Adrenocortical Carcinoma (ACC)-Mouhammed A. Habra, Aung Naing -- Agnostic to Tumor Site-Gerald S. Falchook -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)-Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb -- Bladder Carcinoma (Urothelial Cancer)-Arlene O. Siefker-Radtke -- Brain Tumors-Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer-Senthil Damodaran, Debu Tripathy ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Colorectal Cancer-David S. Hong, E. Scott Kopetz, Allan A. L. Pereira -- Esophageal Cancer (Squamous Cell)-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Gastric/Gastroesophageal Junction Adenocarcinoma-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Head and Neck Cancer-Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer-Vivek Subbiah, Nizar M. Tannir -- Leukemia-Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular)-Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen -- Lung Cancer-Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC -- SCLC -- Lymphoma-Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin. | |
| 505 | 8 | |a Bortezomib -- Bosutinib -- Brentuximab Vedotin -- Brexucabtagene Autoleucel -- Brigatinib -- Brivanib Alaninate -- Bryostatin 1 -- Buparlisib -- Cabozantinib -- Camrelizumab -- Capivasertib -- Capmatinib -- Carfilzomib -- Cediranib Maleate -- Cemiplimab -- Ceritinib -- Cetuximab -- Cevostamab -- Ciltacabtagene Autoleucel -- Cixutumumab -- Cobimetinib Fumarate -- Copanlisib -- Crenolanib Besylate -- Crizotinib -- Dabrafenib -- Dacomitinib -- Dactolisib -- Danvatirsen -- Daratumumab -- Darolutamide -- Darovasertib -- Dasatinib -- Debio-1347 -- Demcizumab -- Dostarlimab -- Double Antiangiogenic Protein -- Dovitinib -- Durvalumab -- Duvelisib -- Elotuzumab -- Enasidenib Mesylate -- Encorafenib -- Enfortumab Vedotin -- Ensartinib -- Entrectinib -- Enzalutamide -- Enzastaurin -- Epratuzumab -- Erdafitinib -- Erlotinib -- Everolimus -- Farletuzumab -- Ficlatuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Fulvestrant -- Futibatinib -- Galunisertib -- Ganitumab -- Gefitinib -- Geldanamycin -- Gemtuzumab Ozogamicin -- Gilteritinib Fumarate -- Glasdegib Maleate -- Ibrutinib -- Icotinib -- Idecabtagene Vicleucel -- Idelalisib -- Imatinib Mesylate -- Imifoplatin397 -- Iniparib -- Inotuzumab Ozogamicin -- Ipafricept -- Ipatasertib -- Ipilimumab -- Isatuximab -- Ivosidenib -- Lanreotide -- Lapatinib Ditosylate -- Larotrectinib -- Lenalidomide -- Lenvatinib Mesylate -- LGK974 -- Linifanib -- Linsitinib -- Loncastuximab Tesirine -- Lorlatinib -- Lucitanib -- Lurbinectedin -- Lutetium Lu 177 Dotatate -- Margetuximab-cmkb -- Matuzumab -- Midostaurin -- Milademetan -- Miransertib -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1 -- Mocetinostat -- Mogamulizumab-kpkc -- Momelotinib -- nab-Rapamycin -- Napabucasin -- Naquotinib Mesylate -- Navitoclax -- Nazartinib -- Necitumumab -- Neratinib -- Nilotinib -- Nintedanib -- Niraparib. | |
| 505 | 8 | |a Nirogacestat -- Nivolumab -- Obatoclax Mesylate -- Obinutuzumab -- Ofatumumab -- Olaparib -- Olaratumab -- Olmutinib -- Onartuzumab -- Onatasertib -- Osimertinib -- Pacritinib -- Palbociclib -- Panitumumab -- Panobinostat -- Parsaclisib -- Pazopanib Hydrochloride -- Pelareorep -- Pembrolizumab -- Pemetrexed -- Pemigatinib -- Peposertib -- Perifosine -- Pertuzumab -- Pexidartinib -- Pilaralisib -- Pimasertib -- Pomalidomide -- Ponatinib Hydrochloride -- Poziotinib -- Pralatrexate -- Pralsetinib -- Prexasertib -- Pyrotinib -- Quizartinib -- Ramucirumab -- Razuprotafib -- RC48-ADC -- Rebastinib -- Refametinib -- Regorafenib -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Ripretinib -- Rituximab -- Romidepsin -- Rovalpituzumab Tesirine -- Rucaparib Camsylate -- Ruxolitinib Phosphate -- Sacituzumab Govitecan -- Sapanisertib -- Saracatinib -- Selinexor -- Selitrectinib -- Selpercatinib -- Selumetinib -- Serabelisib -- Sintilimab -- Sipuleucel-T -- Sirolimus -- Sitravatinib -- Sonidegib -- Sonolisib -- Sorafenib -- Sotatercept -- Sotorasib -- Spartalizumab -- Sunitinib -- TAK580 -- Taladegib -- Talazoparib Tosylate -- Taletrectinib -- Talimogene Laherparepvec -- Talquetamab -- Tazemetostat Hydrobromide -- Teclistamab -- Telaglenastat -- Telatinib -- Temsirolimus -- Tepotinib -- Thalidomide -- Tipifarnib -- Tirabrutinib -- Tisagenlecleucel -- Tisotumab Vedotin-tftv -- Tivantinib -- Toripalimab -- Trabectedin -- Trabedersen -- Trametinib -- Trastuzumab -- Trebananib -- Tremelimumab -- Tucatinib -- Ulixertinib -- Uprosertib -- Urelumab -- Vadastuximab Talirine -- Valproic Acid -- Vandetanib -- Vanucizumab -- Vatalanib -- Veliparib -- Vemurafenib -- Venetoclax -- Vevorisertib -- Vismodegib -- Vistusertib -- Vocimagene Amiretrorepvec -- Vopratelimab -- Vorinostat -- Xentuzumab -- Zalutumumab -- Zanidatamab -- Zanubrutinib -- Ziv-Aflibercept -- Zotatifin. | |
| 650 | 0 | |a Tumors |x Chemotherapy |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Drugs |x Testing |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Clinical trials |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Cancer |x Treatment |v Handbooks, manuals, etc. | |
| 650 | 6 | |a Tumeurs |x Chimiothérapie |v Guides, manuels, etc. | |
| 650 | 6 | |a Médicaments |x Essais cliniques |v Guides, manuels, etc. | |
| 650 | 6 | |a Études cliniques |v Guides, manuels, etc. | |
| 650 | 6 | |a Cancer |x Traitement |v Guides, manuels, etc. | |
| 655 | 7 | |a handbooks. |2 aat | |
| 655 | 7 | |a Handbooks and manuals. |2 lcgft |0 http://id.loc.gov/authorities/genreForms/gf2014026109 | |
| 655 | 7 | |a Guides et manuels. |2 rvmgf | |
| 700 | 1 | |a Karp, Daniel D., |e editor. |0 http://id.loc.gov/authorities/names/n2014186800 | |
| 700 | 1 | |a Falchook, Gerald S., |e editor. |0 http://id.loc.gov/authorities/names/n2014186801 | |
| 700 | 1 | |a Lim, JoAnn D., |e editor. | |
| 966 | 4 | 0 | |l DE-862 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3696453 |3 Volltext |
| 966 | 4 | 0 | |l DE-863 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3696453 |3 Volltext |
| 938 | |a EBSCOhost |b EBSC |n 3696453 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-862 | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1434576124 |
|---|---|
| _version_ | 1829095382192226304 |
| adam_text | |
| any_adam_object | |
| author2 | Karp, Daniel D. Falchook, Gerald S. Lim, JoAnn D. |
| author2_role | edt edt edt |
| author2_variant | d d k dd ddk g s f gs gsf j d l jd jdl |
| author_GND | http://id.loc.gov/authorities/names/n2014186800 http://id.loc.gov/authorities/names/n2014186801 |
| author_facet | Karp, Daniel D. Falchook, Gerald S. Lim, JoAnn D. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.C5 H36 2023 |
| callnumber-search | RC271.C5 H36 2023 |
| callnumber-sort | RC 3271 C5 H36 42023 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgments -- Contents -- SECTION 1 Targets by Organ Site -- Color Key -- Abbreviations -- Adrenocortical Carcinoma (ACC)-Mouhammed A. Habra, Aung Naing -- Agnostic to Tumor Site-Gerald S. Falchook -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)-Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb -- Bladder Carcinoma (Urothelial Cancer)-Arlene O. Siefker-Radtke -- Brain Tumors-Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer-Senthil Damodaran, Debu Tripathy ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Colorectal Cancer-David S. Hong, E. Scott Kopetz, Allan A. L. Pereira -- Esophageal Cancer (Squamous Cell)-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Gastric/Gastroesophageal Junction Adenocarcinoma-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Head and Neck Cancer-Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer-Vivek Subbiah, Nizar M. Tannir -- Leukemia-Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular)-Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen -- Lung Cancer-Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC -- SCLC -- Lymphoma-Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin. Bortezomib -- Bosutinib -- Brentuximab Vedotin -- Brexucabtagene Autoleucel -- Brigatinib -- Brivanib Alaninate -- Bryostatin 1 -- Buparlisib -- Cabozantinib -- Camrelizumab -- Capivasertib -- Capmatinib -- Carfilzomib -- Cediranib Maleate -- Cemiplimab -- Ceritinib -- Cetuximab -- Cevostamab -- Ciltacabtagene Autoleucel -- Cixutumumab -- Cobimetinib Fumarate -- Copanlisib -- Crenolanib Besylate -- Crizotinib -- Dabrafenib -- Dacomitinib -- Dactolisib -- Danvatirsen -- Daratumumab -- Darolutamide -- Darovasertib -- Dasatinib -- Debio-1347 -- Demcizumab -- Dostarlimab -- Double Antiangiogenic Protein -- Dovitinib -- Durvalumab -- Duvelisib -- Elotuzumab -- Enasidenib Mesylate -- Encorafenib -- Enfortumab Vedotin -- Ensartinib -- Entrectinib -- Enzalutamide -- Enzastaurin -- Epratuzumab -- Erdafitinib -- Erlotinib -- Everolimus -- Farletuzumab -- Ficlatuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Fulvestrant -- Futibatinib -- Galunisertib -- Ganitumab -- Gefitinib -- Geldanamycin -- Gemtuzumab Ozogamicin -- Gilteritinib Fumarate -- Glasdegib Maleate -- Ibrutinib -- Icotinib -- Idecabtagene Vicleucel -- Idelalisib -- Imatinib Mesylate -- Imifoplatin397 -- Iniparib -- Inotuzumab Ozogamicin -- Ipafricept -- Ipatasertib -- Ipilimumab -- Isatuximab -- Ivosidenib -- Lanreotide -- Lapatinib Ditosylate -- Larotrectinib -- Lenalidomide -- Lenvatinib Mesylate -- LGK974 -- Linifanib -- Linsitinib -- Loncastuximab Tesirine -- Lorlatinib -- Lucitanib -- Lurbinectedin -- Lutetium Lu 177 Dotatate -- Margetuximab-cmkb -- Matuzumab -- Midostaurin -- Milademetan -- Miransertib -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1 -- Mocetinostat -- Mogamulizumab-kpkc -- Momelotinib -- nab-Rapamycin -- Napabucasin -- Naquotinib Mesylate -- Navitoclax -- Nazartinib -- Necitumumab -- Neratinib -- Nilotinib -- Nintedanib -- Niraparib. Nirogacestat -- Nivolumab -- Obatoclax Mesylate -- Obinutuzumab -- Ofatumumab -- Olaparib -- Olaratumab -- Olmutinib -- Onartuzumab -- Onatasertib -- Osimertinib -- Pacritinib -- Palbociclib -- Panitumumab -- Panobinostat -- Parsaclisib -- Pazopanib Hydrochloride -- Pelareorep -- Pembrolizumab -- Pemetrexed -- Pemigatinib -- Peposertib -- Perifosine -- Pertuzumab -- Pexidartinib -- Pilaralisib -- Pimasertib -- Pomalidomide -- Ponatinib Hydrochloride -- Poziotinib -- Pralatrexate -- Pralsetinib -- Prexasertib -- Pyrotinib -- Quizartinib -- Ramucirumab -- Razuprotafib -- RC48-ADC -- Rebastinib -- Refametinib -- Regorafenib -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Ripretinib -- Rituximab -- Romidepsin -- Rovalpituzumab Tesirine -- Rucaparib Camsylate -- Ruxolitinib Phosphate -- Sacituzumab Govitecan -- Sapanisertib -- Saracatinib -- Selinexor -- Selitrectinib -- Selpercatinib -- Selumetinib -- Serabelisib -- Sintilimab -- Sipuleucel-T -- Sirolimus -- Sitravatinib -- Sonidegib -- Sonolisib -- Sorafenib -- Sotatercept -- Sotorasib -- Spartalizumab -- Sunitinib -- TAK580 -- Taladegib -- Talazoparib Tosylate -- Taletrectinib -- Talimogene Laherparepvec -- Talquetamab -- Tazemetostat Hydrobromide -- Teclistamab -- Telaglenastat -- Telatinib -- Temsirolimus -- Tepotinib -- Thalidomide -- Tipifarnib -- Tirabrutinib -- Tisagenlecleucel -- Tisotumab Vedotin-tftv -- Tivantinib -- Toripalimab -- Trabectedin -- Trabedersen -- Trametinib -- Trastuzumab -- Trebananib -- Tremelimumab -- Tucatinib -- Ulixertinib -- Uprosertib -- Urelumab -- Vadastuximab Talirine -- Valproic Acid -- Vandetanib -- Vanucizumab -- Vatalanib -- Veliparib -- Vemurafenib -- Venetoclax -- Vevorisertib -- Vismodegib -- Vistusertib -- Vocimagene Amiretrorepvec -- Vopratelimab -- Vorinostat -- Xentuzumab -- Zalutumumab -- Zanidatamab -- Zanubrutinib -- Ziv-Aflibercept -- Zotatifin. |
| ctrlnum | (OCoLC)1434576124 |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | Third edition. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>07712cam a2200541 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1434576124</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20250103110447.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu|||unuuu</controlfield><controlfield tag="008">240521s2023 pau of 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCO</subfield><subfield code="d">QGK</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781975179267</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1975179269</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781975179243</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1434576124</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC271.C5</subfield><subfield code="b">H36 2023</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.994061</subfield><subfield code="2">23/eng/20240523</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Handbook of targeted cancer therapy and immunotherapy /</subfield><subfield code="c">editers, Daniel D. Karp, Gerald S. Falchook, JoAnn D. Lim.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Third edition.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia :</subfield><subfield code="b">Wolters Kluwer,</subfield><subfield code="c">[2023]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed May 23, 2024).</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgments -- Contents -- SECTION 1 Targets by Organ Site -- Color Key -- Abbreviations -- Adrenocortical Carcinoma (ACC)-Mouhammed A. Habra, Aung Naing -- Agnostic to Tumor Site-Gerald S. Falchook -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)-Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb -- Bladder Carcinoma (Urothelial Cancer)-Arlene O. Siefker-Radtke -- Brain Tumors-Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer-Senthil Damodaran, Debu Tripathy ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Colorectal Cancer-David S. Hong, E. Scott Kopetz, Allan A. L. Pereira -- Esophageal Cancer (Squamous Cell)-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Gastric/Gastroesophageal Junction Adenocarcinoma-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Head and Neck Cancer-Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer-Vivek Subbiah, Nizar M. Tannir -- Leukemia-Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular)-Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen -- Lung Cancer-Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC -- SCLC -- Lymphoma-Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Bortezomib -- Bosutinib -- Brentuximab Vedotin -- Brexucabtagene Autoleucel -- Brigatinib -- Brivanib Alaninate -- Bryostatin 1 -- Buparlisib -- Cabozantinib -- Camrelizumab -- Capivasertib -- Capmatinib -- Carfilzomib -- Cediranib Maleate -- Cemiplimab -- Ceritinib -- Cetuximab -- Cevostamab -- Ciltacabtagene Autoleucel -- Cixutumumab -- Cobimetinib Fumarate -- Copanlisib -- Crenolanib Besylate -- Crizotinib -- Dabrafenib -- Dacomitinib -- Dactolisib -- Danvatirsen -- Daratumumab -- Darolutamide -- Darovasertib -- Dasatinib -- Debio-1347 -- Demcizumab -- Dostarlimab -- Double Antiangiogenic Protein -- Dovitinib -- Durvalumab -- Duvelisib -- Elotuzumab -- Enasidenib Mesylate -- Encorafenib -- Enfortumab Vedotin -- Ensartinib -- Entrectinib -- Enzalutamide -- Enzastaurin -- Epratuzumab -- Erdafitinib -- Erlotinib -- Everolimus -- Farletuzumab -- Ficlatuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Fulvestrant -- Futibatinib -- Galunisertib -- Ganitumab -- Gefitinib -- Geldanamycin -- Gemtuzumab Ozogamicin -- Gilteritinib Fumarate -- Glasdegib Maleate -- Ibrutinib -- Icotinib -- Idecabtagene Vicleucel -- Idelalisib -- Imatinib Mesylate -- Imifoplatin397 -- Iniparib -- Inotuzumab Ozogamicin -- Ipafricept -- Ipatasertib -- Ipilimumab -- Isatuximab -- Ivosidenib -- Lanreotide -- Lapatinib Ditosylate -- Larotrectinib -- Lenalidomide -- Lenvatinib Mesylate -- LGK974 -- Linifanib -- Linsitinib -- Loncastuximab Tesirine -- Lorlatinib -- Lucitanib -- Lurbinectedin -- Lutetium Lu 177 Dotatate -- Margetuximab-cmkb -- Matuzumab -- Midostaurin -- Milademetan -- Miransertib -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1 -- Mocetinostat -- Mogamulizumab-kpkc -- Momelotinib -- nab-Rapamycin -- Napabucasin -- Naquotinib Mesylate -- Navitoclax -- Nazartinib -- Necitumumab -- Neratinib -- Nilotinib -- Nintedanib -- Niraparib.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Nirogacestat -- Nivolumab -- Obatoclax Mesylate -- Obinutuzumab -- Ofatumumab -- Olaparib -- Olaratumab -- Olmutinib -- Onartuzumab -- Onatasertib -- Osimertinib -- Pacritinib -- Palbociclib -- Panitumumab -- Panobinostat -- Parsaclisib -- Pazopanib Hydrochloride -- Pelareorep -- Pembrolizumab -- Pemetrexed -- Pemigatinib -- Peposertib -- Perifosine -- Pertuzumab -- Pexidartinib -- Pilaralisib -- Pimasertib -- Pomalidomide -- Ponatinib Hydrochloride -- Poziotinib -- Pralatrexate -- Pralsetinib -- Prexasertib -- Pyrotinib -- Quizartinib -- Ramucirumab -- Razuprotafib -- RC48-ADC -- Rebastinib -- Refametinib -- Regorafenib -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Ripretinib -- Rituximab -- Romidepsin -- Rovalpituzumab Tesirine -- Rucaparib Camsylate -- Ruxolitinib Phosphate -- Sacituzumab Govitecan -- Sapanisertib -- Saracatinib -- Selinexor -- Selitrectinib -- Selpercatinib -- Selumetinib -- Serabelisib -- Sintilimab -- Sipuleucel-T -- Sirolimus -- Sitravatinib -- Sonidegib -- Sonolisib -- Sorafenib -- Sotatercept -- Sotorasib -- Spartalizumab -- Sunitinib -- TAK580 -- Taladegib -- Talazoparib Tosylate -- Taletrectinib -- Talimogene Laherparepvec -- Talquetamab -- Tazemetostat Hydrobromide -- Teclistamab -- Telaglenastat -- Telatinib -- Temsirolimus -- Tepotinib -- Thalidomide -- Tipifarnib -- Tirabrutinib -- Tisagenlecleucel -- Tisotumab Vedotin-tftv -- Tivantinib -- Toripalimab -- Trabectedin -- Trabedersen -- Trametinib -- Trastuzumab -- Trebananib -- Tremelimumab -- Tucatinib -- Ulixertinib -- Uprosertib -- Urelumab -- Vadastuximab Talirine -- Valproic Acid -- Vandetanib -- Vanucizumab -- Vatalanib -- Veliparib -- Vemurafenib -- Venetoclax -- Vevorisertib -- Vismodegib -- Vistusertib -- Vocimagene Amiretrorepvec -- Vopratelimab -- Vorinostat -- Xentuzumab -- Zalutumumab -- Zanidatamab -- Zanubrutinib -- Ziv-Aflibercept -- Zotatifin.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Tumors</subfield><subfield code="x">Chemotherapy</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Testing</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Clinical trials</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Tumeurs</subfield><subfield code="x">Chimiothérapie</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Essais cliniques</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Études cliniques</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cancer</subfield><subfield code="x">Traitement</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">handbooks.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Handbooks and manuals.</subfield><subfield code="2">lcgft</subfield><subfield code="0">http://id.loc.gov/authorities/genreForms/gf2014026109</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Guides et manuels.</subfield><subfield code="2">rvmgf</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karp, Daniel D.,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014186800</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Falchook, Gerald S.,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014186801</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lim, JoAnn D.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-862</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3696453</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-863</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3696453</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">3696453</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-862</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | handbooks. aat Handbooks and manuals. lcgft http://id.loc.gov/authorities/genreForms/gf2014026109 Guides et manuels. rvmgf |
| genre_facet | handbooks. Handbooks and manuals. Guides et manuels. |
| id | ZDB-4-EBA-on1434576124 |
| illustrated | Not Illustrated |
| indexdate | 2025-04-11T08:48:08Z |
| institution | BVB |
| isbn | 9781975179267 1975179269 |
| language | English |
| oclc_num | 1434576124 |
| open_access_boolean | |
| owner | MAIN DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| physical | 1 online resource. |
| psigel | ZDB-4-EBA FWS_PDA_EBA ZDB-4-EBA |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | Wolters Kluwer, |
| record_format | marc |
| spelling | Handbook of targeted cancer therapy and immunotherapy / editers, Daniel D. Karp, Gerald S. Falchook, JoAnn D. Lim. Third edition. Philadelphia : Wolters Kluwer, [2023] 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier Online resource; title from PDF title page (EBSCO, viewed May 23, 2024). Includes index. Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgments -- Contents -- SECTION 1 Targets by Organ Site -- Color Key -- Abbreviations -- Adrenocortical Carcinoma (ACC)-Mouhammed A. Habra, Aung Naing -- Agnostic to Tumor Site-Gerald S. Falchook -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)-Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb -- Bladder Carcinoma (Urothelial Cancer)-Arlene O. Siefker-Radtke -- Brain Tumors-Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer-Senthil Damodaran, Debu Tripathy ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Colorectal Cancer-David S. Hong, E. Scott Kopetz, Allan A. L. Pereira -- Esophageal Cancer (Squamous Cell)-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Gastric/Gastroesophageal Junction Adenocarcinoma-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Head and Neck Cancer-Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer-Vivek Subbiah, Nizar M. Tannir -- Leukemia-Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular)-Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen -- Lung Cancer-Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC -- SCLC -- Lymphoma-Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin. Bortezomib -- Bosutinib -- Brentuximab Vedotin -- Brexucabtagene Autoleucel -- Brigatinib -- Brivanib Alaninate -- Bryostatin 1 -- Buparlisib -- Cabozantinib -- Camrelizumab -- Capivasertib -- Capmatinib -- Carfilzomib -- Cediranib Maleate -- Cemiplimab -- Ceritinib -- Cetuximab -- Cevostamab -- Ciltacabtagene Autoleucel -- Cixutumumab -- Cobimetinib Fumarate -- Copanlisib -- Crenolanib Besylate -- Crizotinib -- Dabrafenib -- Dacomitinib -- Dactolisib -- Danvatirsen -- Daratumumab -- Darolutamide -- Darovasertib -- Dasatinib -- Debio-1347 -- Demcizumab -- Dostarlimab -- Double Antiangiogenic Protein -- Dovitinib -- Durvalumab -- Duvelisib -- Elotuzumab -- Enasidenib Mesylate -- Encorafenib -- Enfortumab Vedotin -- Ensartinib -- Entrectinib -- Enzalutamide -- Enzastaurin -- Epratuzumab -- Erdafitinib -- Erlotinib -- Everolimus -- Farletuzumab -- Ficlatuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Fulvestrant -- Futibatinib -- Galunisertib -- Ganitumab -- Gefitinib -- Geldanamycin -- Gemtuzumab Ozogamicin -- Gilteritinib Fumarate -- Glasdegib Maleate -- Ibrutinib -- Icotinib -- Idecabtagene Vicleucel -- Idelalisib -- Imatinib Mesylate -- Imifoplatin397 -- Iniparib -- Inotuzumab Ozogamicin -- Ipafricept -- Ipatasertib -- Ipilimumab -- Isatuximab -- Ivosidenib -- Lanreotide -- Lapatinib Ditosylate -- Larotrectinib -- Lenalidomide -- Lenvatinib Mesylate -- LGK974 -- Linifanib -- Linsitinib -- Loncastuximab Tesirine -- Lorlatinib -- Lucitanib -- Lurbinectedin -- Lutetium Lu 177 Dotatate -- Margetuximab-cmkb -- Matuzumab -- Midostaurin -- Milademetan -- Miransertib -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1 -- Mocetinostat -- Mogamulizumab-kpkc -- Momelotinib -- nab-Rapamycin -- Napabucasin -- Naquotinib Mesylate -- Navitoclax -- Nazartinib -- Necitumumab -- Neratinib -- Nilotinib -- Nintedanib -- Niraparib. Nirogacestat -- Nivolumab -- Obatoclax Mesylate -- Obinutuzumab -- Ofatumumab -- Olaparib -- Olaratumab -- Olmutinib -- Onartuzumab -- Onatasertib -- Osimertinib -- Pacritinib -- Palbociclib -- Panitumumab -- Panobinostat -- Parsaclisib -- Pazopanib Hydrochloride -- Pelareorep -- Pembrolizumab -- Pemetrexed -- Pemigatinib -- Peposertib -- Perifosine -- Pertuzumab -- Pexidartinib -- Pilaralisib -- Pimasertib -- Pomalidomide -- Ponatinib Hydrochloride -- Poziotinib -- Pralatrexate -- Pralsetinib -- Prexasertib -- Pyrotinib -- Quizartinib -- Ramucirumab -- Razuprotafib -- RC48-ADC -- Rebastinib -- Refametinib -- Regorafenib -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Ripretinib -- Rituximab -- Romidepsin -- Rovalpituzumab Tesirine -- Rucaparib Camsylate -- Ruxolitinib Phosphate -- Sacituzumab Govitecan -- Sapanisertib -- Saracatinib -- Selinexor -- Selitrectinib -- Selpercatinib -- Selumetinib -- Serabelisib -- Sintilimab -- Sipuleucel-T -- Sirolimus -- Sitravatinib -- Sonidegib -- Sonolisib -- Sorafenib -- Sotatercept -- Sotorasib -- Spartalizumab -- Sunitinib -- TAK580 -- Taladegib -- Talazoparib Tosylate -- Taletrectinib -- Talimogene Laherparepvec -- Talquetamab -- Tazemetostat Hydrobromide -- Teclistamab -- Telaglenastat -- Telatinib -- Temsirolimus -- Tepotinib -- Thalidomide -- Tipifarnib -- Tirabrutinib -- Tisagenlecleucel -- Tisotumab Vedotin-tftv -- Tivantinib -- Toripalimab -- Trabectedin -- Trabedersen -- Trametinib -- Trastuzumab -- Trebananib -- Tremelimumab -- Tucatinib -- Ulixertinib -- Uprosertib -- Urelumab -- Vadastuximab Talirine -- Valproic Acid -- Vandetanib -- Vanucizumab -- Vatalanib -- Veliparib -- Vemurafenib -- Venetoclax -- Vevorisertib -- Vismodegib -- Vistusertib -- Vocimagene Amiretrorepvec -- Vopratelimab -- Vorinostat -- Xentuzumab -- Zalutumumab -- Zanidatamab -- Zanubrutinib -- Ziv-Aflibercept -- Zotatifin. Tumors Chemotherapy Handbooks, manuals, etc. Drugs Testing Handbooks, manuals, etc. Clinical trials Handbooks, manuals, etc. Cancer Treatment Handbooks, manuals, etc. Tumeurs Chimiothérapie Guides, manuels, etc. Médicaments Essais cliniques Guides, manuels, etc. Études cliniques Guides, manuels, etc. Cancer Traitement Guides, manuels, etc. handbooks. aat Handbooks and manuals. lcgft http://id.loc.gov/authorities/genreForms/gf2014026109 Guides et manuels. rvmgf Karp, Daniel D., editor. http://id.loc.gov/authorities/names/n2014186800 Falchook, Gerald S., editor. http://id.loc.gov/authorities/names/n2014186801 Lim, JoAnn D., editor. |
| spellingShingle | Handbook of targeted cancer therapy and immunotherapy / Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgments -- Contents -- SECTION 1 Targets by Organ Site -- Color Key -- Abbreviations -- Adrenocortical Carcinoma (ACC)-Mouhammed A. Habra, Aung Naing -- Agnostic to Tumor Site-Gerald S. Falchook -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)-Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb -- Bladder Carcinoma (Urothelial Cancer)-Arlene O. Siefker-Radtke -- Brain Tumors-Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer-Senthil Damodaran, Debu Tripathy ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Colorectal Cancer-David S. Hong, E. Scott Kopetz, Allan A. L. Pereira -- Esophageal Cancer (Squamous Cell)-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Gastric/Gastroesophageal Junction Adenocarcinoma-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Head and Neck Cancer-Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer-Vivek Subbiah, Nizar M. Tannir -- Leukemia-Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular)-Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen -- Lung Cancer-Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC -- SCLC -- Lymphoma-Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin. Bortezomib -- Bosutinib -- Brentuximab Vedotin -- Brexucabtagene Autoleucel -- Brigatinib -- Brivanib Alaninate -- Bryostatin 1 -- Buparlisib -- Cabozantinib -- Camrelizumab -- Capivasertib -- Capmatinib -- Carfilzomib -- Cediranib Maleate -- Cemiplimab -- Ceritinib -- Cetuximab -- Cevostamab -- Ciltacabtagene Autoleucel -- Cixutumumab -- Cobimetinib Fumarate -- Copanlisib -- Crenolanib Besylate -- Crizotinib -- Dabrafenib -- Dacomitinib -- Dactolisib -- Danvatirsen -- Daratumumab -- Darolutamide -- Darovasertib -- Dasatinib -- Debio-1347 -- Demcizumab -- Dostarlimab -- Double Antiangiogenic Protein -- Dovitinib -- Durvalumab -- Duvelisib -- Elotuzumab -- Enasidenib Mesylate -- Encorafenib -- Enfortumab Vedotin -- Ensartinib -- Entrectinib -- Enzalutamide -- Enzastaurin -- Epratuzumab -- Erdafitinib -- Erlotinib -- Everolimus -- Farletuzumab -- Ficlatuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Fulvestrant -- Futibatinib -- Galunisertib -- Ganitumab -- Gefitinib -- Geldanamycin -- Gemtuzumab Ozogamicin -- Gilteritinib Fumarate -- Glasdegib Maleate -- Ibrutinib -- Icotinib -- Idecabtagene Vicleucel -- Idelalisib -- Imatinib Mesylate -- Imifoplatin397 -- Iniparib -- Inotuzumab Ozogamicin -- Ipafricept -- Ipatasertib -- Ipilimumab -- Isatuximab -- Ivosidenib -- Lanreotide -- Lapatinib Ditosylate -- Larotrectinib -- Lenalidomide -- Lenvatinib Mesylate -- LGK974 -- Linifanib -- Linsitinib -- Loncastuximab Tesirine -- Lorlatinib -- Lucitanib -- Lurbinectedin -- Lutetium Lu 177 Dotatate -- Margetuximab-cmkb -- Matuzumab -- Midostaurin -- Milademetan -- Miransertib -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1 -- Mocetinostat -- Mogamulizumab-kpkc -- Momelotinib -- nab-Rapamycin -- Napabucasin -- Naquotinib Mesylate -- Navitoclax -- Nazartinib -- Necitumumab -- Neratinib -- Nilotinib -- Nintedanib -- Niraparib. Nirogacestat -- Nivolumab -- Obatoclax Mesylate -- Obinutuzumab -- Ofatumumab -- Olaparib -- Olaratumab -- Olmutinib -- Onartuzumab -- Onatasertib -- Osimertinib -- Pacritinib -- Palbociclib -- Panitumumab -- Panobinostat -- Parsaclisib -- Pazopanib Hydrochloride -- Pelareorep -- Pembrolizumab -- Pemetrexed -- Pemigatinib -- Peposertib -- Perifosine -- Pertuzumab -- Pexidartinib -- Pilaralisib -- Pimasertib -- Pomalidomide -- Ponatinib Hydrochloride -- Poziotinib -- Pralatrexate -- Pralsetinib -- Prexasertib -- Pyrotinib -- Quizartinib -- Ramucirumab -- Razuprotafib -- RC48-ADC -- Rebastinib -- Refametinib -- Regorafenib -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Ripretinib -- Rituximab -- Romidepsin -- Rovalpituzumab Tesirine -- Rucaparib Camsylate -- Ruxolitinib Phosphate -- Sacituzumab Govitecan -- Sapanisertib -- Saracatinib -- Selinexor -- Selitrectinib -- Selpercatinib -- Selumetinib -- Serabelisib -- Sintilimab -- Sipuleucel-T -- Sirolimus -- Sitravatinib -- Sonidegib -- Sonolisib -- Sorafenib -- Sotatercept -- Sotorasib -- Spartalizumab -- Sunitinib -- TAK580 -- Taladegib -- Talazoparib Tosylate -- Taletrectinib -- Talimogene Laherparepvec -- Talquetamab -- Tazemetostat Hydrobromide -- Teclistamab -- Telaglenastat -- Telatinib -- Temsirolimus -- Tepotinib -- Thalidomide -- Tipifarnib -- Tirabrutinib -- Tisagenlecleucel -- Tisotumab Vedotin-tftv -- Tivantinib -- Toripalimab -- Trabectedin -- Trabedersen -- Trametinib -- Trastuzumab -- Trebananib -- Tremelimumab -- Tucatinib -- Ulixertinib -- Uprosertib -- Urelumab -- Vadastuximab Talirine -- Valproic Acid -- Vandetanib -- Vanucizumab -- Vatalanib -- Veliparib -- Vemurafenib -- Venetoclax -- Vevorisertib -- Vismodegib -- Vistusertib -- Vocimagene Amiretrorepvec -- Vopratelimab -- Vorinostat -- Xentuzumab -- Zalutumumab -- Zanidatamab -- Zanubrutinib -- Ziv-Aflibercept -- Zotatifin. Tumors Chemotherapy Handbooks, manuals, etc. Drugs Testing Handbooks, manuals, etc. Clinical trials Handbooks, manuals, etc. Cancer Treatment Handbooks, manuals, etc. Tumeurs Chimiothérapie Guides, manuels, etc. Médicaments Essais cliniques Guides, manuels, etc. Études cliniques Guides, manuels, etc. Cancer Traitement Guides, manuels, etc. |
| subject_GND | http://id.loc.gov/authorities/genreForms/gf2014026109 |
| title | Handbook of targeted cancer therapy and immunotherapy / |
| title_auth | Handbook of targeted cancer therapy and immunotherapy / |
| title_exact_search | Handbook of targeted cancer therapy and immunotherapy / |
| title_full | Handbook of targeted cancer therapy and immunotherapy / editers, Daniel D. Karp, Gerald S. Falchook, JoAnn D. Lim. |
| title_fullStr | Handbook of targeted cancer therapy and immunotherapy / editers, Daniel D. Karp, Gerald S. Falchook, JoAnn D. Lim. |
| title_full_unstemmed | Handbook of targeted cancer therapy and immunotherapy / editers, Daniel D. Karp, Gerald S. Falchook, JoAnn D. Lim. |
| title_short | Handbook of targeted cancer therapy and immunotherapy / |
| title_sort | handbook of targeted cancer therapy and immunotherapy |
| topic | Tumors Chemotherapy Handbooks, manuals, etc. Drugs Testing Handbooks, manuals, etc. Clinical trials Handbooks, manuals, etc. Cancer Treatment Handbooks, manuals, etc. Tumeurs Chimiothérapie Guides, manuels, etc. Médicaments Essais cliniques Guides, manuels, etc. Études cliniques Guides, manuels, etc. Cancer Traitement Guides, manuels, etc. |
| topic_facet | Tumors Chemotherapy Handbooks, manuals, etc. Drugs Testing Handbooks, manuals, etc. Clinical trials Handbooks, manuals, etc. Cancer Treatment Handbooks, manuals, etc. Tumeurs Chimiothérapie Guides, manuels, etc. Médicaments Essais cliniques Guides, manuels, etc. Études cliniques Guides, manuels, etc. Cancer Traitement Guides, manuels, etc. handbooks. Handbooks and manuals. Guides et manuels. |
| work_keys_str_mv | AT karpdanield handbookoftargetedcancertherapyandimmunotherapy AT falchookgeralds handbookoftargetedcancertherapyandimmunotherapy AT limjoannd handbookoftargetedcancertherapyandimmunotherapy |